Daniel Meling

Mr. Daniel Meling

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2024 in Psychoactives
Verified
Journal Article
Open access
PDF file
DMDaniel Meling
Daniel Meling
RERebecca Ehrenkranz
Rebecca Ehrenkranz
SNSandeep M. Nayak
Sandeep M. Nayak
HAHelena Aicher
Helena Aicher
XFXaver Funk
Xaver Funk
DYDavid Bryce Yaden
David Bryce Yaden
Rationale: Psychedelic research re-emerged from a period of suppression into the so-called psychedelic renaissance. In parallel, most media reporting has shifted from the overstatement of the risks of psychedelics to overly positive hype. As the empirical evidence is more equivocal than frequently portrayed, the conclusions about the effectiveness of psychedelics should be considered preliminary. Poor science communication about psychedelics’ therapeutic potential may lead potential participants or patients to feel misled and policy decisions to be misinformed. An evidence-informed characterization of their risks and benefits is needed. Objectives: This article assesses the state of psychedelic research for treating depression and the effect sizes of psychedelics on therapeutic outcomes, the risk of bias, and the prevalence of adverse effects. We review research on the risks and benefits of psychedelics and discuss how the following depression treatments have shown decreasing effect sizes over time: (1) cognitive behavioral therapy, (2) mindfulness interventions, (3) selective serotonin reuptake inhibitors, and (4) ketamine. We speculate that a similar trend may occur for psychedelic treatments. Results and conclusions: It is likely that larger and better-controlled psychedelic trials will demonstrate smaller effect sizes that are more comparable to other conventional and emerging treatments for mood disorders. Clear science communication is critical for setting public expectations and psychedelic policy. With this evidence-based assessment, we aim to cut through the misinformation about the benefits, risks, and future prospects of psychedelic treatments.

3 April 2023 in Frontiers in Psychology
Verified
Journal Article
Open access
DMDaniel Meling
Daniel Meling
MSMilan Scheidegger
Milan Scheidegger
Psychedelics are psychoactive substances that receive renewed interest from science and society. Increasing empirical evidence shows that the effects of psychedelics are associated with alterations in biochemical processes, brain activity, and lived experience. Still, how these different levels relate remains subject to debate. The current literature presents two influential views on the relationship between the psychedelic molecule, neural events, and experience: The integration view and the pluralistic view. The main aim of this article is to contribute a promising complementary view by re-evaluating the psychedelic molecule-brain-experience relationship from an enactive perspective. We approach this aim via the following main research questions: (1) What is the causal relationship between the psychedelic drug and brain activity? (2) What is the causal relationship between brain activity and the psychedelic experience? In exploring the first research question, we apply the concept of autonomy to the psychedelic molecule-brain relationship. In exploring the second research question, we apply the concept of dynamic co-emergence to the psychedelic brain-experience relationship. Addressing these two research questions from an enactive position offers a perspective that emphasizes interdependence and circular causality on multiple levels. This enactive perspective not only supports the pluralistic view but enriches it through a principled account of how multi-layered processes come to interact. This renders the enactive view a promising contribution to questions around causality in the therapeutic effects of psychedelics with important implications for psychedelic therapy and psychedelic research.

8 February 2025 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
KEKlemens Egger
Klemens Egger
JRJavier Jareño Redondo
Javier Jareño Redondo
JMJovin Müller
Jovin Müller
JDJoëlle Dornbierer
Joëlle Dornbierer
JSJohn Smallridge
John Smallridge
DDDario A. Dornbierer
Dario A. Dornbierer
Ayahuasca, a traditional psychoactive Amazonian brew, usually contains N,N-dimethyltryptamine (DMT) and β-carboline (harmine, harmaline, tetrahydroharmine) monoamine oxidase inhibitors. However, the pharmacological interactions between these compounds remain incompletely understood. In this study, we developed an ayahuasca-inspired formulation containing DMT and harmine, aiming to systematically evaluate their pharmacokinetic and pharmacodynamic drug-drug interactions (DDI) across a range of dosage levels. We hypothesized that escalating harmine doses would enhance DMT bioavailability, increase its plasma half-life, and reduce the variability in DMT plasma concentrations between individuals. Additionally, we expected that harmine would attenuate the plasma levels of the main DMT metabolite, indole-3-acetic acid (3-IAA), while increasing levels of the secondary metabolite DMT-N-oxide (DMT-NO). This single-blind, randomized, two-arm, factorial, dose-finding study included 16 healthy participants (9 males, 7 females), each receiving six dose combinations (0-120 mg DMT, 0-180 mg harmine) administered via a microcarrier-based transmucosal delivery system. We then evaluated the pharmacokinetics of DMT and harmine and their main metabolites, subjective effects, autonomic responses, and the safety profile of the combined preparation. All DMT-harmine combinations reliably induced dose-dependent subjective effects lasting 4-5 h, with peak DMT and harmine levels (Cmax) reaching 33 ng/mL and 49 ng/mL, respectively. Tmax, the time to maximum concentrations, increased with dose escalation for both compounds. The interactions between DMT and harmine were not unidirectional, i.e., harmine reduced the metabolism of DMT, while DMT altered harmine pharmacokinetics. Our novel formulation demonstrated a favorable safety profile, supporting its potential for further testing in patients with various affective disorders.

27 September 2024 in Journal of Psychopharmacology
Verified
Journal Article
Open access
DMDaniel Meling
Daniel Meling
KEKlemens Egger
Klemens Egger
HAHelena D Aicher
Helena D Aicher
JRJavier Jareño Redondo
Javier Jareño Redondo
JMJovin Mueller
Jovin Mueller
MSMilan Scheidegger
Milan Scheidegger
Background: In recent years, both meditation and psychedelics have attracted rapidly increasing scientific interest. While the current state of evidence suggests the promising potential of psychedelics, such as psilocybin, to enhance meditative training, it remains equivocal whether these effects are specifically bound to psilocybin or if other classical psychedelics might show synergistic effects with meditation practice. One particularly promising candidate is N,N-dimethyltryptamine (DMT), an active ingredient of ayahuasca. Aim: This study aims to investigate the effect of the psychedelic substance DMT, combined with the monoamine oxidase inhibitor harmine ( DMT-harmine), on meditative states, compared to meditation with a placebo. Method: Forty experienced meditators (18 females and 22 males) participated in a double-blind, placebo-controlled study over a 3-day meditation retreat, receiving either placebo or DMT-harmine. Participants’ levels of mindfulness, compassion, insight, and transcendence were assessed before, during, and after the meditation group retreat, using psychometric questionnaires. Results: Compared to meditation with a placebo, meditators who received DMT and harmine self-attributed greater levels of mystical-type experiences, non-dual awareness, and emotional breakthrough during the acute substance effects and, when corrected for baseline differences, greater psychological insight 1 day later. Mindfulness and compassion were not significantly different in the DMT-harmine group compared to placebo. At 1-month follow-up, the meditators who received DMT and harmine rated their experience as significantly more personally meaningful, spiritually significant, and well-being-enhancing than the meditators who received placebo. Conclusion: Investigating the impact of DMT-harmine on meditators in a naturalistic mindfulness group retreat, this placebo-controlled study highlights the specific effects of psychedelics during meditation. Trial registration: ClinicalTrials.gov identifier NCT05780216.

29 April 2025 in NeuroImage
Verified
Journal Article
Open access
DSDila Suay
Dila Suay
HAHelena Aicher
Helena Aicher
MKMicheal Kometer
Micheal Kometer
MMMichael J. Mueller
Michael J. Mueller
LCLuzia Caflisch
Luzia Caflisch
DBDavide Bottari
Davide Bottari
Psychedelics are known to profoundly alter perception and self-referential processing, yet their specific effects on face recognition -particularly regarding recognition of face familiarity-remain underexplored. This study investigates the effects of an ayahuasca-inspired novel DMT/HAR (N,N-dimethyltryptamine/Harmine) formulation and Harmine alone on face recognition and self-referential processing, as measured by event-related potentials (ERPs) and subjective behavioral measures. In a within-subject, double-blind, placebo-controlled design, 30 healthy male participants underwent EEG recording during a visual oddball task involving Self, Familiar, and Unknown Faces. The study compared the effects of a DMT/HAR formulation, harmine alone, and placebo on key visual ERP components: P1, N170, and P300. DMT/HAR enhanced early visual processing (P1) but attenuated structural encoding (N170) across all face categories, suggesting altered perceptual integration. Crucially, DMT/HAR selectively reduced P300 amplitudes for self-faces, blurring the neural differentiation between self-other faces at posterior sites. Concurrently, frontal electrodes showed increased self-face responses and decreased unknown-face responses, indicating a dynamic reorganization of self-referential salience rather than a general dissolution of self-boundaries. Familiar face processing remained stable across conditions, suggesting that socially meaningful representations were preserved despite psychedelic-induced perceptions shifts. These findings reveal that psychedelics reshape self-referential processing by balancing perceptual instability with compensatory cognitive mechanisms, leading to a restructuring rather than an erasure of self-boundaries. This reorganization of self-salience may underlie the therapeutic effects of psychedelics in disorders characterized by rigid self-processing, such as depression and social anxiety. By reducing neural differentiation between self and others, psychedelics may facilitate flexibility in social and emotional processing, offering new insights into their potential clinical applications.

16 December 2025 in Philosophical Psychology
Verified
Journal Article
Closed access
HBHüseyin Beyköylü
Hüseyin Beyköylü
JVJohn Vervaeke
John Vervaeke
DMDaniel Meling
Daniel Meling